Bio-Techne Corp

Chart & Performance

D1W1MN

P/E

69.29

P/S

10.05

EPS

1.06

Div Yield, %

0.43%

Shrs. gr., 5y

0.66%

Rev. gr., 5y

10.17%

Revenues

1.16b

+1.97%

Net income

168m

-41.07%

CFO

299m

+17.53%

Dividend

Aug 19, 20240.08 USD/sh

Earnings

Jan 30, 2025

Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

URL

https://www.bio-techne.com/

IPO date

Feb 09, 1989

Employees

3,050

Domiciled in

Incorporated in

Valuation

Order:

Title USD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title USD in thousands, except ratios and share amounts	2024‑06	2023‑06	2022‑06	2021‑06	2020‑06	2019‑06	2018‑06	2017‑06	2016‑06	2015‑06
Income
Revenues	1,159,060 1.97%	1,136,702 2.81%	1,105,599 18.75%
Cost of revenue	882,825	837,758	809,009
Unusual Expense (Income)
NOPBT	276,235	298,944	296,590
NOPBT Margin	23.83%	26.30%	26.83%
Operating Taxes	17,584	53,217	38,287
Tax Rate	6.37%	17.80%	12.91%
NOPAT	258,651	245,727	258,303
Net income	168,105 -41.07%	285,263 4.86%	272,051 93.75%
Dividends	(50,419)	(50,285)	(50,185)
Dividend yield	0.44%	0.38%	0.35%
Proceeds from repurchase of equity	(80,042)	(19,562)	(83,795)
BB yield	0.69%	0.15%	0.59%
Debt
Debt current	25,840	22,398	24,428
Long-term debt	507,156	548,731	371,604
Deferred revenue		1,531	2,094
Other long-term liabilities	69,020	99,901	15,145
Net debt	127,983	455,801	112,977
Cash flow
Cash from operating activities	298,981	254,393	325,272
CAPEX	(62,877)	(38,244)	(44,908)
Cash from investing activities	(203,030)	(265,649)	(96,851)
Cash from financing activities	(122,398)	22,616	(242,853)
FCF	229,098	93,853	195,179
Balance
Cash	152,863	204,310	247,029
Long term investments	252,150	(88,982)	36,026
Excess cash	347,060	58,493	227,775
Stockholders' equity	1,248,513	1,244,973	1,047,354
Invested Capital	2,223,268	2,385,106	1,803,209
ROIC	11.23%	11.73%	13.78%
ROCE	10.75%	11.80%	13.92%
EV
Common stock shares outstanding	160,774	161,855	164,116
Price	71.65 -12.23%	81.63 -5.80%	86.66 -23.01%
Market cap	11,519,457 -12.81%	13,212,224 -7.10%	14,222,293 -21.98%
EV	11,647,440	13,668,025	14,334,511
EBITDA	387,946	406,182	397,659
EV/EBITDA	30.02	33.65	36.05
Interest	15,736	11,215	11,309
Interest/NOPBT	5.70%	3.75%	3.81%